Safety of everolimus plus exemestane in patients with hormone-receptor–positive, HER2–negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)-Reference-Cited by-同舟云学术

Safety of everolimus plus exemestane in patients with hormone-receptor–positive, HER2–negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)

Published:2016-09 Issue:9 Volume:27 Page:1719-1725
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Jerusalem G.,Mariani G.,Ciruelos E.M.,Martin M.,Tjan-Heijnen V.C.G.,Neven P.,Gavila J.G.,Michelotti A.,Montemurro F.,Generali D.,Simoncini E.,Lang I.,Mardiak J.,Naume B.,Camozzi M.,Lorizzo K.,Bianchetti S.,Conte P.

Funder

Novartis Pharmaceuticals Corporation

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/9/1719/19446741/mdw249.pdf

Reference17 articles.

1. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2);Cardoso;Ann Oncol,2014

2. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial;Nabholtz;J Clin Oncol,2000

3. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group;Mouridsen;J Clin Oncol,2003